Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
(PR NEWSWIRE) DNAPrint Announces the Release of RETINOME(TM) for the Forensic M
rket: Eye Color Prediction From Crime Scene DNA!
DNAPrint Announces the Release of RETINOME(TM) for the Forensic Market: Eye Colo
Prediction From Crime Scene DNA!
SARASOTA, Fla., Aug. 17 /PRNewswire-FirstCall/ -- DNAPrint genomics, Inc.
announced today that it has finished validating an ultra-high throughput
version of its proprietary RETINOME(TM) genetic test for predicting human
(eye) iris color from DNA. The new test has been added to the Company's
proprietary DNAWitness(TM) 2.5 physical profiling package of genome tests sold
to forensics and security investigators.
The completion of the RETINOME(TM) project and the addition of the new
RETINOME(TM) product to the Company's DNAWitness(TM) package of genome tests
constitute a dramatic advance in the newly developing science of molecular
forensics profiling, where the goal is to paint a physical profile from crime
scene DNA.
RETINOME(TM) provides an accurate inference of iris (eye) color from the
measurement of proprietary single nucleotide polymorphisms (SNPs) distributed
throughout the human genome. The genetic basis of this trait has vexed
geneticists for decades. As detailed in an article published in a recent
'Trends in Genetics' review article, RETINOME(TM) was developed from a genome
screen of tens of thousands of genome SNPs in thousands of European subjects.
A necessary but not sufficient component of the RETINOME(TM) technology was
first published by DNAPrint(TM) scientists last spring in the peer-reviewed
journal, "Genetics." Since the discovery of the genetic keys for predicting
iris color from DNA 3 years ago, the Company has been augmenting, evaluating
and optimizing the performance of its innovative RETINOME(TM) genome test.
The most recent blind validation test for 65 individuals of predominant (>80%)
European ancestry, between the ages of 10 and 60 years, showed greater than
97% accuracy. A "blind" test is one in which a model is used to classify a
trait for samples that were not used to develop the model in any way, and
provides an indication of the generality of the model for field application.
DNAPrint's computer scientists developed innovative and proprietary software
that proved to be the key to unlocking the door to this difficult trait.
"As a presumptive test designed for investigative, rather than human
identity applications which suggest culpability, a 97% accuracy rate
corresponds to a solid 'A' grade," said Zach Gaskin. "The test is appropriate
for samples that have typed with the Company's DNAWitness(TM) 2.5 test to be
of predominant European continental ancestry, and was blindly validated
strictly for individuals of both sexes between the ages of 10 and 60 years."
The validation and commercial implementation of RETINOME(TM) using this
powerful approach is a historic event; RETINOME(TM) becomes the first test
developed and validated for the inference of a complex genetics trait from
DNA. Prior to the human genome era, complex genetics traits such as disease
proclivity, drug response and particularly physical traits such as iris and
hair color vexed geneticists for decades. The excitement generated by the
completion of the human genome sequence draft in 2001 was based on the hope
that common human traits would finally be understood from a genetics
perspective. The ultimate expression of genetic understanding is demonstrated
by showing an ability to predict or infer a trait from DNA sequences, but so
far this hope has remained largely unfulfilled. Prior to RETINOME(TM), no
predictive genome-based test had been developed, described in the peer-
reviewed literature or, most importantly, launched commercially. DNAPrint's
ability to do so stems from its innovative approach for screening the human
genome that feeds from the mathematical fuel provided by natural human
population structure. "We are very proud to be the first to demonstrate how
the promise of the human genome project can be fulfilled in a practical
sense," said Tony Frudakis, DNAPrint's Chief Scientific Officer.
"DNAPrint's success with this difficult trait has profound implications
for its goal of developing a pipeline of small molecule drugs that target
specific human subpopulations," said Richard Gabriel, CEO and President.
"More immediately, a grant is available from the National Institutes of
Justice and can be found at: http://www.ojp.usdoj.gov/nij/funding.htm and is
specific for 'Solving Cold Cases with DNA.' Now not only can we tell the
genetic profile of the crime scene DNA, but we can also describe the eye color
if their DNA genetic results fall into the correct category. Each time we do
this, we are reducing the "donor pool" of individuals and the number of
suspects. Combining our DNAWitness(TM) technology with RETINOME(TM) and
standard STR testing, as well as mitochondrial and y-Chromosome testing, this
is a powerful combination of information for the investigators. Our photo
database system of images, coupled with an eye color prediction, are just the
beginning of our forensic products for the investigative community. We intend
to aggressively roll out additional services over the next several years to
enhance the predictive ability of our Company's products and services from
crime scene DNA."
RETINOME(TM) is available today along with DNAWitness(TM) and can be
ordered directly from any of the following companies: DNAPrint genomics, Inc.
http://www.dnaprint.com ; ReliaGene Technologies, Inc.
http://www.reliagene.com and Lynn Peavey Company http://www.lynnpeavey.com .
About ReliaGene Technologies, Inc.
Founded in 1990 and based in the New Orleans, LA metro area, ReliaGene
Technologies Inc. is a leading DNA laboratory facility specializing in human
genetic identification and related bio-tech product development. With
cutting-edge capabilities for forensic and paternity DNA testing, ReliaGene
has now successfully detected human genetic profiles from over 400,000
biological samples, including cases from all 50 U.S. states and over 35
countries worldwide. ReliaGene's Y-PLEX(TM) genotyping systems, first
released in 2000, are now sold in over 40 countries with market demand
increasing steadily. DNAWitness is available through ReliaGene and for more
information, please visit: http://www.reliagene.com.
About Lynn Peavey Company
Lynn Peavey is the leader in providing law enforcement with forensic
innovations for use at the crime scene and in the laboratory. Lynn Peavey
reaches over 17,000 law enforcement agencies, medical examiners and crime
laboratories across the country. The Lynn Peavey Company has an on-line
catalog and bound catalog by request for all crime scene materials and
including a DNAWitness testing kit. For more information, please visit:
http://www.lynnpeavey.com
About DNAPrint genomics, Inc.
DNAPrint genomics Inc. uses proprietary human genome research methods to
develop genomic-based services and products. The Company introduced
Ancestrybydna in the consumer market and DNAWitness in the forensic market in
2003. DNAPrint is developing products in the pharmacogenomic market and has a
disease gene discovery program. The Company is traded on the NASDAQ OTC
Bulletin Board under the ticker symbol: DNAP. For more information about the
company, please visit: http://www.dnaprint.com.
All statements in this press release that are not historical are forward-
looking statements within the meaning of Section 21E of the Securities
Exchange Act as amended. Such statements are subject to risks and
uncertainties that could cause actual results to differ materially from those
projected, including, but not limited to, uncertainties relating to
technologies, product development, manufacturing, market acceptance, cost and
pricing of DNAPrint's products, dependence on collaborations and partners,
regulatory approvals, competition, intellectual property of others, and patent
protection and litigation. DNAPrint genomics, Inc. expressly disclaims any
obligation or undertaking to release publicly any updates or revisions to any
forward-looking statements contained herein to reflect any change in
DNAPrint's expectations with regard thereto or any change in events,
conditions, or circumstances on which any such statements are based.
Media and Press Contacts
Richard Gabriel
DNAPrint genomics, Inc.
CEO/President
(941) 366-3400
SOURCE DNAPrint genomics, Inc.
-0- 08/17/2004
/CONTACT: Richard Gabriel, CEO/President, DNAPrint Genomics, Inc.,
+1-941-366-3400/
/Web site: http://www.dnaprint.com
http://www.reliagene.com
http://www.lynnpeavey.com /
(DNAP)
CO: DNAPrint genomics, Inc.; ReliaGene Technologies, Inc.; Lynn Peavey
Company
ST: Florida
IN: MTC OTC
SU: PDT
*** end of story ***
(COMTEX) B: DNAPrint genomics Is Encouraging Law Enforcement Agencies to I
clude DNAWitness(TM) in Their NIJ Grant Proposals ( P
B: DNAPrint genomics Is Encouraging Law Enforcement Agencies to Include DNAWitne
s(TM) in Their NIJ Grant Proposals ( PRNewswire-FirstCall )
SARASOTA, Fla., Aug 16, 2004 /PRNewswire-FirstCall via COMTEX/ -- A grant for
solving cold cases with DNA is being offered by the National Institute of
Justice and has an upcoming application deadline of September 7. The money is
slated for the development of solutions for identifying cold cases with viable
DNA evidence that can be analyzed and uploaded into the FBI's Combined DNA Index
System (CODIS). DNAPrint (OTC Bulletin Board: DNAP) would like agencies applying
for the grant money to include an "additional testing" section in their budget
proposals for tests such as Y-chromosome, mitochondrial and single nucleotide
polymorphism (SNP) testing.
CODIS enables federal, state and local crime labs to exchange and compare DNA
profiles electronically, thereby linking crimes to each other and to convicted
offenders. Currently, there are over 1.7 million convicted offender profiles and
84,477 forensic profiles in the national database. CODIS's primary metric, the
"Investigation Aided," is defined as a case that CODIS assisted through a hit (a
match produced by CODIS that would not otherwise have been developed). As of
June 2004, CODIS has produced over 15,100 hits assisting in more than 18,100
investigations.
When DNA from cold cases is entered into CODIS and does not match with convicted
offenders or other cases, investigators have had few options but to wait until
the suspect commits another crime. Now investigators have the choice of using
DNAWitness(TM) to gain quality information about the ancestry of the
perpetrator. The ancestry profile can be used to infer the general
characteristics of what the perpetrator looks like and can help eliminate whole
populations of people.
DNAWitness(TM) is an SNP-based test that determines the perpetrator's
proportions of European, East Asian, Native American and Sub-Saharan African
strictly from the DNA. This enables detectives to submit DNA from a crime scene
and rapidly develop a profile of general physical appearance. The investigative
efforts can then be focused, leads filtered and money saved. More importantly,
DNAWitness(TM) can lead to a speedy arrest, which could save the lives of other
citizens.
DNAWitness(TM) is a novel investigative tool that could be used on the
aforementioned 84,477 forensic profiles in CODIS, which represent the growing
number of cold cases in the United States. DNAWitness(TM) has already had
notable success in several cases, including a recent high profile case involving
the Louisiana serial killer Derrick Todd Lee. Lee was captured two months after
investigators received a report that the unknown perpetrator was 85% Sub-Saharan
African and 15% Native American. This information helped change the focus of the
investigation. Lee was convicted on August 11, 2004 for the murder of Geralyn
Barr DeSoto. DNAPrint continues to encourage federal officials and policy makers
to make DNAWitness(TM) the next logical step in criminal investigations when no
matches are found in CODIS.
Dr. Patrick O'Donnell, Supervising Criminalist for the San Diego Police
Department and early sample panel contributor to the evaluation of
DNAWitness(TM), is puzzled that more agencies are not taking advantage of this
remarkable technology. "For decades, law enforcement agencies have been willing
to submit cases for behavioral profiling, and yet this practice has proven to be
of questionable value in solving cases. Here is a scientific technology in
DNAWitness(TM) that provides ancestral information based on the large-scale
analysis of genetic polymorphisms, and the test appears underutilized."
O'Donnell continued, "How many agencies have had a rape series where victims or
witnesses have given conflicting physical descriptions of the perpetrator, or
homicide cases with absolutely no clue as to ancestry of the perpetrator, where
DNAWitness(TM) could provide reliable information essential to solving the
case?"
Across the United States there are hundreds of Cold Case units that can use
DNAWitness(TM) and other DNA testing services to help open cold cases and help
re-direct their investigations. DNAPrint genomics, Inc. has created a service
that will continue to improve with time. Currently, a customer will receive the
DNAWitness(TM) profile, photo database examples of people with similar profiles
(all volunteers) and a complete short tandem repeat (STR) profile consistent
with that used by the CODIS system. The company uses the STR profile to "bar
code" the sample and helps retain sample identity for the chain of custody.
"We will be contacting as many agencies, police and investigators as possible
over the next two to three weeks, right up to the last minute, to try and
encourage investigators and grant submitters to include DNAWitness(TM) as a part
of their grant proposals," said Zach Gaskin, Technical Coordinator of Forensics
at DNAPrint genomics, Inc. "We are also encouraging grant applicants to use
other DNA testing services, such as ReliaGene's Y-Chromosome STR test, that
helped convict Derrick Todd Lee, and mitochondrial DNA testing. The current
landscape of forensic DNA testing is changing and we simply want to make sure
that investigators realize all the tools they have for identifying perpetrators.
Grant funding will be a key element," Gaskin pointed out. "Every forensic sample
in CODIS should be profiled using DNAWitness(TM), and those cold cases destined
for CODIS are no different," he concluded.
The grant application can be found on line at
http://www.ojp.usdoj.gov/nij/funding.htm .
"We are encouraging everyone we can to help get DNAWitness(TM) onto the grant,
as well as other DNA testing services," said Richard Gabriel, CEO and President.
"We will be working the phones to encourage everyone to fill out the grant
application and include us," he said. "Additionally, one of our distributors,
ReliaGene Technologies, Inc., is also ready to assist in helping grant
applicants. Their Y-Chromosome STR tests, along with CODIS STR testing, are
valuable tools when combined with DNAWitness(TM). We are the one-two punch that
will help narrow the investigation and identify perpetrators, helping convict
the criminals. We are at the crossroads for DNA testing, this is a chance that
law enforcement has been begging for and we have a service, DNAWitness(TM), that
can help investigators focus on the best leads, reducing time, saving lives and
using the Federal resources allocated for that purpose. The title of this grant
says it all: 'Solving Cold Cases with DNA'!"
About ReliaGene Technologies, Inc.
Founded in 1990 and based in the New Orleans, LA metro area, ReliaGene
Technologies Inc. is a leading DNA laboratory facility specializing in human
genetic identification and related bio-tech product development. With
cutting-edge capabilities for forensic and paternity DNA testing, ReliaGene has
now successfully detected human genetic profiles from over 400,000 biological
samples, including cases from all 50 U.S. states and over 35 countries
worldwide. ReliaGene's Y-PLEX(TM) genotyping systems, first released in 2000,
are now sold in over 40 countries with market demand increasing steadily.
DNAWitness is available through ReliaGene. For more information, please visit:
http://www.reliagene.com .
About DNAPrint genomics, Inc.
DNAPrint genomics, Inc. uses proprietary human genome research methods to
develop genomic-based services and products. The Company introduced
Ancestrybydna in the consumer market and DNAWitness in the forensic market in
2003. DNAPrint is developing products in the pharmacogenomic market and has a
disease gene discovery program. The Company is traded on the Nasdaq OTC Bulletin
Board under the ticker symbol: DNAP. For more information about the Company,
please visit: http://www.dnaprint.com .
All statements in this press release that are not historical are forward-
looking statements within the meaning of Section 21E of the Securities Exchange
Act as amended. Such statements are subject to risks and uncertainties that
could cause actual results to differ materially from those projected, including,
but not limited to, uncertainties relating to technologies, product development,
manufacturing, market acceptance, cost and pricing of DNAPrint's products,
dependence on collaborations and partners, regulatory approvals, competition,
intellectual property of others, and patent protection and litigation. DNAPrint
genomics, Inc. expressly disclaims any obligation or undertaking to release
publicly any updates or revisions to any forward-looking statements contained
herein to reflect any change in DNAPrint's expectations with regard thereto or
any change in events, conditions, or circumstances on which any such statements
are based.
Media and Press Contacts
Richard Gabriel
DNAPrint genomics, Inc. CEO/President (941) 366-3400
SOURCE DNAPrint genomics, Inc.
CONTACT: Richard Gabriel, CEO and President, DNAPrint genomics, Inc.,
+1-941-366-3400
URL: http://www.dnaprint.com
http://www.prnewswire.com
Copyright (C) 2004 PR Newswire. All rights reserved.
-0-
KEYWORD: Florida
Louisiana
INDUSTRY KEYWORD: MTC
OTC
BIO
HEA
SUBJECT CODE: OTC
*** end of story ***
(PR NEWSWIRE) DNAWitness(TM) Leads Investigators to the Right Man: Louisiana Se
ial Killer Convicted
DNAWitness(TM) Leads Investigators to the Right Man: Louisiana Serial Killer Con
icted
SARASOTA, Fla., Aug. 12 /PRNewswire-FirstCall/ -- DNAPrint genomics
(OTC Bulletin Board: DNAP) announces that the success of DNAWitness(TM) came
full circle as jurors in a Port Allen courtroom returned an 11-1 guilty
verdict for the man known as the Louisiana Serial killer, Derrick Todd Lee.
This case was the first forensic case in which DNAPrint genomics'
DNAWitness(TM) completely changed the direction of the investigation and
helped lead to the capture of the prime suspect.
DNAWitness(TM) is a test that investigators can use to narrow their field
of DNA donors based on ancestry information gained from examining DNA left at
the crime scene. The test determines proportional European, East Asian,
Native American, and Sub-Saharan African ancestry on a 0-100% scale. It also
reports the proportions of mixture among these four continental groups on a
100% scale and compares the suspect's profile from a crime scene sample to a
photographic database of volunteers to give the investigator an aid in
interpreting the profile. DNAWitness(TM) is an investigative tool that has
been used by several agencies in the United States, Canada, and Great Britain.
"This test can have a profound impact on how fast we capture suspects,"
said Zach Gaskin, Technical Coordinator of Forensics at DNAPrint. "In the Lee
case, the investigators had to go on the information that was available from
the eyewitnesses. Unfortunately eyewitnesses can and often do, have many flaws
in their stories. In this case, the main flaw was that eyewitnesses identified
the perpetrator as a white male, which led the detectives in the completely
wrong direction."
DNAWitness(TM) was utilized in this investigation in March 2003 and
reported that the unknown suspect was majority sub-Saharan African, dispelling
the notion that the perpetrator was Caucasian. Circumstantial eyewitness
accounts led investigators to focus on Caucasian males for more than a year
while the killing continued. Approximately two months after the DNAWitness(TM)
report was issued to authorities and combined with other information, they had
Lee in custody.
Investigators in the Lee case opted to perform a "DNA sweep" or "DNA
dragnet" of thousands of potential donors to try to match or eliminate
possible donors from the DNA profile found linking the serial killer's
victims. "Finding your donor by collection from the random man on the street
is statistically difficult, but in this case, all the evidence was pointing to
the wrong donor profile and they had no choice. This kind of a sweep can cost
a police department its yearly budget," said Gaskin. "Especially if the police
are looking in the wrong donor group. Had our test been available and used at
the beginning of this investigation, we could have saved them a tremendous
amount of money. It would have helped them narrow the search and re-focus
their investigation. DNAWitness(TM) has the potential to save lives as well by
getting violent criminals off the street quickly. How many investigations are
being neglected because manpower and resources are being wasted chasing the
wrong lead?"
DNAPrint reports that a high percentage of the DNAWitness(TM) cases that
come to them are heading in the wrong direction. "The gut feeling and
sometimes the eyewitness are just not good enough anymore," said Richard
Gabriel, Chief Executive Officer and President of DNAPrint. "We are providing
scientific evidence that takes the guesswork out of many cases. This test can
change the way we look at the investigative process. A person's life is too
important to let a case with DNA evidence transition into a cold case. I think
the lesson to be learned by the Lee case is that the technology of
DNAWitness(TM) can make a difference. Investigators need to ask themselves if
any cases they have, past or present, can benefit by knowing the genetic
ancestry of their suspect and having access to a photo database array of
similar looking DNA donors. We are at a profound crossroads for DNAWitness(TM)
and we hope everyone in the investigative community, from detectives to
prosecutors to medical examiners and forensic scientists, will opt to use this
new tool. It is available from Lynn Peavey Company, ReliaGene Technologies,
Inc. and directly from us. As the first successful conviction of a
DNAWitness(TM) case, the Lee conviction was a major hurdle for our presumptive
test. It should be clear to everyone that DNAWitness(TM) is a service that can
help catch criminals."
About ReliaGene Technologies, Inc.
Founded in 1990 and based in the New Orleans, LA metro area, ReliaGene
Technologies Inc. is a leading DNA laboratory facility specializing in human
genetic identification and related bio-tech product development. With
cutting-edge capabilities for forensic and paternity DNA testing, ReliaGene
has now successfully detected human genetic profiles from over 400,000
biological samples, including cases from all 50 U.S. states and over 35
countries worldwide. ReliaGene's Y-PLEX(TM) genotyping systems, first
released in 2000, are now sold in over 40 countries with market demand
increasing steadily. DNAWitness is available through ReliaGene and for more
information, please visit: http://www.reliagene.com.
About Lynn Peavey Company
Lynn Peavey is the leader in providing law enforcement with forensic
innovations for use at the crime scene and in the laboratory. Lynn Peavey
reaches over 17,000 law enforcement agencies, medical examiners and crime
laboratories across the country. The Lynn Peavey Company has an on-line
catalog and bound catalog by request for all crime scene materials and
including a DNAWitness testing kit. For more information, please visit:
http://www.lynnpeavey.com.
About DNAPrint genomics, Inc.
DNAPrint genomics Inc. uses proprietary human genome research methods to
develop genomic-based services and products. The Company introduced
Ancestrybydna in the consumer market and DNAWitness in the forensic market in
2003. DNAPrint is developing products in the pharmacogenomic market and has a
disease gene discovery program. The Company is traded on the NASDAQ OTC
Bulletin Board under the ticker symbol: DNAP. For more information about the
company, please visit: http://www.dnaprint.com.
All statements in this press release that are not historical are forward-
looking statements within the meaning of Section 21E of the Securities
Exchange Act as amended. Such statements are subject to risks and
uncertainties that could cause actual results to differ materially from those
projected, including, but not limited to, uncertainties relating to
technologies, product development, manufacturing, market acceptance, cost and
pricing of DNAPrint's products, dependence on collaborations and partners,
regulatory approvals, competition, intellectual property of others, and patent
protection and litigation. DNAPrint genomics, Inc. expressly disclaims any
obligation or undertaking to release publicly any updates or revisions to any
forward-looking statements contained herein to reflect any change in
DNAPrint's expectations with regard thereto or any change in events,
conditions, or circumstances on which any such statements are based.
Media and Press Contacts:
Richard Gabriel
DNAPrint genomics, Inc. CEO/President (941) 366-3400
SOURCE DNAPrint genomics, Inc.
-0- 08/12/2004
/CONTACT: Richard Gabriel, CEO/President, DNAPrint genomics, Inc.,
+1-941-366-3400/
/Web site: http://www.dnaprint.com/
(DNAP)
CO: DNAPrint genomics, Inc.; ReliaGene Technologies, Inc.;
Lynn Peavey Company
ST: Florida
IN: MTC OTC
SU:
*** end of story ***
(PR NEWSWIRE) DNAPrint Notches Another Publication
DNAPrint Notches Another Publication
SARASOTA, Fla., July 26 /PRNewswire-FirstCall/ -- DNAPrint genomics
(OTC Bulletin Board: DNAP) (the "Company") announces today that its Chief
Scientific Officer, Dr. Tony Frudakis, has co-authored a survey article in the
peer-reviewed journal "Trends in Genetics."
The article, entitled "Eye colour: portals into pigmentation genes and
ancestry" (Sturm, R. and T. Frudakis, Trends in Genetics, 20(8) 327-332),
discusses a number of exciting recent developments relating to the genetics of
human iris color. Last year, DNAPrint published data linking certain gene
sequence variants to human iris color. Subsequent publications by other
authors confirmed DNAPrint's primary findings that the human OCA2 gene is the
primary determinant of human iris color (Zhu, G. et al. 2004. A genome scans
for eye colour in 502 twin families: most variation is due to a QTL on
chromosome 15q. Twin Res 7, 197-210).
Rick Sturm, a pigmentation genetics expert from the University of
Queensland, Brisbane Australia, co-authored the survey. Sturm's laboratory
and the laboratory of Rick Martin (Queensland Institute of Medical Research,
Brisbane Australia), from which the Zhu, et. al. paper originated, contacted
DNAPrint last year and the three groups have been collaborating since.
"It is very gratifying that others have confirmed our work, and that the
editors of a respected journal desire to review the research to which we are
contributing," said Tony Frudakis, Chief Scientific Officer of DNAPrint
genomics, Inc.
About DNAPrint genomics, Inc.
DNAPrint genomics Inc. uses proprietary human genome research methods to
develop genomic-based services and products. The Company introduced
ANCESTRYbyDNA(TM) in the consumer market and DNAWitness(TM) in the forensic
market in 2003. DNAPrint(TM) is developing products in the pharmacogenomic
market and has a disease gene discovery program. The Company is traded on the
Nasdaq OTC Bulletin Board under the ticker symbol: DNAP. For more information
about the company, please visit http://www.dnaprint.com.
All statements in this press release that are not historical are forward-
looking statements within the meaning of Section 21E of the Securities
Exchange Act as amended. Such statements are subject to risks and
uncertainties that could cause actual results to differ materially from those
projected, including, but not limited to, uncertainties relating to
technologies, product development, manufacturing, market acceptance, cost and
pricing of DNAPrint's products, dependence on collaborations and partners,
regulatory approvals, competition, intellectual property of others, and patent
protection and litigation. DNAPrint genomics, Inc. expressly disclaims any
obligation or undertaking to release publicly any updates or revisions to any
forward-looking statements contained herein to reflect any change in
DNAPrint's expectations with regard thereto or any change in events,
conditions, or circumstances on which any such statements are based.
Media and Press Contacts
Richard Gabriel
DNAPrint genomics, Inc.
CEO/President
(941) 366-3400
SOURCE DNAPrint genomics, Inc.
-0- 07/26/2004
/CONTACT: Richard Gabriel, CEO and President, DNAPrint genomics, Inc.,
+1-941-366-3400/
/Web site: http://www.dnaprint.com /
(DNAP)
CO: DNAPrint genomics, Inc.
ST: Florida
IN: MTC BIO OTC
SU: SVY
*** end of story ***
(PR NEWSWIRE) DNAPrint Technology Featured in 'Nature' Journal Review and Upcom
ng Textbook
DNAPrint Technology Featured in 'Nature' Journal Review and Upcoming Textbook
SARASOTA, Fla., July 22 /PRNewswire-FirstCall/ -- DNAPrint genomics
(OTC Bulletin Board: "DNAP") (the "Company") announces today that its
ANCESTRYbyDNA(TM) 2.5 product will be featured in a review article to be
published next month in the journal "Nature Reviews." The article will focus
on the growing interest in personal anthropology and will highlight the
uniqueness of DNAPrint's role in this growing market. The article represents
the first discussion of the Company's proprietary BioGeographical Ancestry
(BGA) admixture test in the peer-reviewed literature.
In addition, at the invitation of Academic Press Publishers, DNAPrint's
Chief Scientific Officer has agreed to co-author a textbook on the history,
molecular genetics, mathematics and practice of molecular photo fitting
entitled "Molecular Photo Fitting: Predicting Ancestry and Phenotype Using
DNA." Dr. Mark Shriver, a co-author of the Nature Review article, was invited
by DNAPrint to join the project as a co-author. The Company expects the work,
targeted for publication March 1, 2006, to serve as the interface between the
Company's unique pharmacogenomics/forensics platform and the scientific
community.
About DNAPrint genomics, Inc.
DNAPrint genomics Inc. uses proprietary human genome research methods to
develop genomic-based services and products. The Company introduced
ANCESTRYbyDNA in the consumer market and DNAWitness in the forensic market in
2003. DNAPrint is developing products in the pharmacogenomic market and has a
disease gene discovery program. The Company is traded on the Nasdaq OTC
Bulletin Board under the ticker symbol: DNAP. For more information about the
company, please visit http://www.dnaprint.com.
All statements in this press release that are not historical are forward-
looking statements within the meaning of Section 21E of the Securities
Exchange Act, as amended. Such statements are subject to risks and
uncertainties that could cause actual results to differ materially from those
projected, including, but not limited to, uncertainties relating to
technologies, product development, manufacturing, market acceptance, cost and
pricing of DNAPrint's products, dependence on collaborations and partners,
regulatory approvals, competition, intellectual property of others, and patent
protection and litigation. DNAPrint genomics, Inc. expressly disclaims any
obligation or undertaking to release publicly any updates or revisions to any
forward-looking statements contained herein to reflect any change in
DNAPrint's expectations with regard thereto or any change in events,
conditions, or circumstances on which any such statements are based.
Media and Press Contacts:
Richard Gabriel
DNAPrint genomics, Inc. CEO/President
(941) 366-3400
SOURCE DNAPrint genomics, Inc.
-0- 07/22/2004
/CONTACT: Richard Gabriel, CEO and President, DNAPrint genomics, Inc.,
+1-941-366-3400/
/Web site: http://www.dnaprint.com/
(DNAP)
CO: DNAPrint genomics, Inc.
ST: Florida
IN: MTC OTC PUB
SU:
*** end of story ***
(PR NEWSWIRE) DNAPrint Upgrades DNAWitness(TM) 2.5; New Information Technology
or Better Physical Profiling
DNAPrint Upgrades DNAWitness(TM) 2.5; New Information Technology for Better Phys
cal Profiling
SARASOTA, Fla., July 22 /PRNewswire-FirstCall/ -- DNAPrint genomics
(OTC Bulletin Board: DNAP) (the "Company") announces today that it has
upgraded its DNAWitness(TM) 2.5 product for physical profiling from DNA with a
proprietary database designed to help investigators learn what their results
say, or don't say, about physical appearance.
The DNAWitness(TM) 2.5 genome test allows forensics investigators to
employ objective science, empiricism and statistical analysis in the
reconstruction of a physical profile or "fuzzy photo" from DNA left at a crime
scene. It employs the world's first molecular genetics test for the inference
of BioGeographical Ancestry (BGA) admixture. For example, DNA at a crime
scene may indicate that a person is of 90% East Asian, 10% European mix. BGA
is obviously related to physical appearance, and individuals with fewer
admixtures tend to have more accentuated anthropometric characteristics (those
that vary from race to race). Investigators who obtain a result such as 100%
East Asian typically have little difficulty interpreting the result, but
investigators who, for example, obtain a result such as 70% European, 30% East
Asian usually ask whether the person's physical appearance would reveal the
East Asian admixture. Communicating how BGA relates to physical appearance is
difficult to do with words in a scientific way, but the advance announced
today is the first solution for this problem.
To project what a person may look like from knowledge of their DNA,
DNAPrint has developed the DNAWitness(TM) 2.5 database of individual BGA
admixture results. The database contains information on how individuals
previously tested have self-defined in terms of ethnicity (called the
"geopolitical" arm of the database) as well as their digital photographs. By
querying the database using a specific BGA admixture result, investigators can
see for themselves what the range of variability is corresponding to that
result for various features, such as skin shade, hair texture, nose shape,
epicanthal eye folding, etc. Whether or not, for example, individuals of 70%
European, 30% East Asian admixture tend to show no East Asian features, would
be apparent from the database query. Statistical tools soon to be added will
allow investigators to use Analysis of Molecular Variance to determine whether
there is a systematic difference in the expression of an anthropometric trait
that can be measured from the photograph in one database sample set versus the
international average, or versus another group. DNAPrint has already filed
patent applications on the use of digital photograph databases and databases
of biographical data with BioGeographical Ancestry admixture data.
Last week, the Company provided a mid-Atlantic customer access to this
database for the first time; all DNAWitness(TM) 2.5 customers from today
forward will enjoy its use.
About DNAPrint genomics, Inc.
DNAPrint genomics, Inc. uses proprietary human genome research methods to
develop genomic-based services and products. The Company introduced
AncestryByDNA in the consumer market and DNAWitness(TM) in the forensic market
in 2003. DNAPrint is developing products in the pharmacogenomic market and has
a disease gene discovery program. The Company is traded on the Nasdaq OTC
Bulletin Board under the ticker symbol: DNAP. For more information about the
company, please visit http://www.dnaprint.com.
All statements in this press release that are not historical are forward-
looking statements within the meaning of Section 21E of the Securities
Exchange Act as amended. Such statements are subject to risks and
uncertainties that could cause actual results to differ materially from those
projected, including, but not limited to, uncertainties relating to
technologies, product development, manufacturing, market acceptance, cost and
pricing of DNAPrint's products, dependence on collaborations and partners,
regulatory approvals, competition, intellectual property of others, and patent
protection and litigation. DNAPrint genomics, Inc. expressly disclaims any
obligation or undertaking to release publicly any updates or revisions to any
forward-looking statements contained herein to reflect any change in
DNAPrint's expectations with regard thereto or any change in events,
conditions, or circumstances on which any such statements are based.
Media and Press Contact
Richard Gabriel
DNAPrint genomics, Inc.
CEO/President
(941) 366-3400
SOURCE DNAPrint genomics, Inc.
-0- 07/22/2004
/CONTACT: Richard Gabriel, CEO and President, DNAPrint genomics, Inc.,
+1-941-366-3400/
/Web site: http://www.dnaprint.com /
(DNAP)
CO: DNAPrint genomics, Inc.
ST: Florida
IN: MTC BIO OTC
SU: PDT
*** end of story ***
(BSNS WIRE) CMKM Diamonds Inc. Announces 'Carolyn Pipe' Lab Results Confirm D
amondiferous Kimberlite
CMKM Diamonds Inc. Announces 'Carolyn Pipe' Lab Results Confirm Diamondiferous K
mberlite
Business Editors
LAS VEGAS--(BUSINESS WIRE)--CMKX--
CMKM Diamonds Inc. (Pink Sheets: CMKX) is very excited
to announce that the "Carolyn Pipe" is confirmed to be diamondiferous.
Saskatchewan Research Council (SRC), an independent lab located in
Saskatoon, Saskatchewan reported to the company today that the core
samples from the "Carolyn Pipe" has come back positive for diamond
content. The "Carolyn Pipe" is located on the jointly owned Smeaton
property in Saskatchewan, Canada held by CMKM Diamonds Inc., being the
primary operator of the claims, United Carina Resources Corp. (CDNX:
UCA), Consolidated Pine Channel Gold Corp. (CDNX: KPG) and U.S.
Canadian Minerals Inc. (OTCBB: UCAD).
www.casavantmining.com
There is no guarantee that further exploration or drilling will
produce any economic benefit to the company or the shareholders of the
company.
This press release contains "forward-looking" statements as that
term is defined by Section 27A of the Securities Act of 1933, as
amended, (the "Securities Act") and Section 21E of the Securities
Exchange Act of 1934, as amended, (the "Exchange Act"). All statements
that are included in this press release other than statements of
historical fact are "forward-looking" statements. Although management
believes that the expectations reflecting in these forward-looking
statements are reasonable, it can give no assurance that such
expectations will prove to have been correct. Important factors could
cause actual results to differ materially from the expectations as
disclosed herein, including without limitation, in conjunction with
these forward-looking statements contained in this press release.
KEYWORD: NEVADA
INDUSTRY KEYWORD: MINING/METALS PRODUCT
SOURCE: CMKM Diamonds Inc.
CONTACT INFORMATION:
CMKM Diamonds Inc.
Diamonds Hotline
Melvin O'Neil, 306-752-3755
Toll-free in U.S./Canada: 877-752-3755
Fax: 306-752-3754
ipr@sasktel.net
*** end of story ***
(BSNS WIRE) J.M. Dutton & Associates Announces Investment Opinion: DNAPrint g
nomics Speculative Buy Rating in Initiating Coverage
J.M. Dutton & Associates Announces Investment Opinion: DNAPrint genomics Specula
ive Buy Rating in Initiating Coverage by Dutton & Associates
Business Editors
EL DORADO HILLS, Calif.--(BUSINESS WIRE)--NOTE TO EDITORS: The following is an
investment opinion issued
by J.M. Dutton & Associates--
J.M. Dutton & Associates initiates coverage of DNAPrint
genomics (OTCBB:DNAP) with a Speculative Buy rating. The 22-page
report by J.M. Dutton senior analyst Sherry Grisewood, CFA is
available at www.jmdutton.com as well as from First Call, Bloomberg,
Zacks, Multex, and other leading financial portals.
DNAPrint genomics is a late-stage development company with
patented leading-edge quantitative genomics classification and
analysis technology. The Company's technology enables the rapid and
cost-effective analysis of DNA material to determine frequency
probabilities of gene locations, and therefore, predict specific
genetic traits in individuals such as Bio-Geographical Ancestry
Admixture or pharmacogenomic profile based upon the frequency of gene
location and other markers present in DNA. The Company has developed
two commercial products from its state-of-the-art proprietary
ADMIXMAP(TM) technology platform for use in forensics and
consumer-oriented genealogy analysis. Both products are now beginning
to generate revenue and will support future product development in
pharmacogenomics diagnostics. The Company is expected to move its
first pharmacogenomic profiling diagnostic product, OVANOME(TM), into
US. clinical trials during 2004. Further, DNAPrint genomics is one of
only a few companies capable of performing high-throughput (25,000
genotypes per day) genotyping analysis. The Company will have to gain
greater acceptance in the forensics market to generate revenues.
DNAPrint genomics faces a number of challenges that are typical of
small capitalization companies.
About Dutton & Associates
Dutton & Associates is one of the largest independent investment
research firms in the U.S. Its 24 senior analysts are primarily CFAs,
and have expertise in many industries. Dutton & Associates provides
continuing analyst coverage of over 70 enrolled companies, and its
research, estimates, and ratings are carried in all the major
databases serving institutions and online investors.
The cost of enrollment in our one-year continuing research program
is US $28,000 prepaid before commencement of our research activities.
We received $28,000 from the Company for coverage for the year, and do
not accept payment of our fees in company stock. Our principals and
analysts are prohibited from owning or trading in securities of
covered companies. The views expressed in this research report
accurately reflect the analyst's personal views about the subject
securities or issuer. Neither the analyst's compensation nor the
compensation received by us is in any way related to the specific
ratings or views contained in this research report or note. Please
read full disclosures and analyst background at www.jmdutton.com
before investing.
KEYWORD: CALIFORNIA
INDUSTRY KEYWORD: MEDICAL
SOURCE: DNAPrint genomics
CONTACT INFORMATION:
J.M. Dutton & Associates, LLC
John M. Dutton, 916/941-8119
*** end of story ***
(PR NEWSWIRE) DNAPrint Launches New Genealogy Products and Service in Family Tr
e Legends
DNAPrint Launches New Genealogy Products and Service in Family Tree Legends
SARASOTA, Fla., May 10 /PRNewswire-FirstCall/ -- DNAPrint genomics
(OTC Bulletin Board: DNAP) of Sarasota, FL announced that it is launching a
new product -- "STR Map" -- to be used for determining paternity and identity
in genealogy testing in the Family Tree Legends web site:
www.familytreelegends.com along with its ANCESTRYbyDNA(TM) 2.5.
DNAPrint genomics is pleased to announce the release of its STR Map
service in conjunction with Pearl Street Software. STR Map uses the
industry's gold standard in Human Identity testing, the same test used by
forensic and paternity labs around the world. The test is based on a genetic
variation known as short tandem repeat or "STR." These genetic markers form a
unique identifying code for each individual, statistically powerful enough for
human identification. The STR Map service allows the consumer to have these
markers typed for their private and confidential use.
By teaming up with Pearl Street Software and its highly rated records
manager software, Family Tree Legends, the usefulness of this service to the
genealogy community grows. The STR Map service adds to the tests and services
already offered by DNAPrint genomics including its popular ANCESTRYbyDNA(TM)
2.5 test, which determines your percentage of Sub-Saharan African, East Asian,
European and Native American.
"We welcome the opportunity to bring customers the benefits of preserving
and further exploring their genetic profiles. This adds a whole new dimension
to the information a genealogist can collect, and by teaming with Pearl Street
Software on this, we add to the value of the information we can provide. This
type of genetic information should enhance our understanding of where we come
from and how our families may interrelate," said Dr. Matt Thomas, Senior
Scientist at DNAPrint(TM).
"As the only records manager that handles DNA, Family Tree Legends
continues to bring genetic genealogy into the fold as a must-have tool for
family historians. With this new release, DNAPrint(TM) has further solidified
itself in the DNA market, and I'm certain the exposure will have more
genealogists using their services," said Cliff Shaw, President and CEO of
Pearl Street Software.
To learn more about STR Map and to order a collection kit, please visit
DNAPrint's web page http://www.ancestrybydna.com/strorder.asp or by phone at
941-366-3400. Information about Pearl Street Software's Family Tree Legends
can be found at http://www.familytreelegends.com/.
About DNAPrint genomics, Inc.
DNAPrint genomics Inc. uses proprietary human genome research methods to
develop genomic-based services and products. The Company introduced
ANCESTRYbyDNA(TM) in the consumer market and DNAWitness(TM) in the forensic
market in 2003. DNAPrint(TM) is developing products in the pharmacogenomic
market and has a disease gene discovery program. The Company is traded on the
Nasdaq OTC Bulletin Board under the ticker symbol: DNAP. For more information
about the company, please visit www.dnaprint.com.
All statements in this press release that are not historical are forward-
looking statements within the meaning of Section 21E of the Securities
Exchange Act as amended. Such statements are subject to risks and
uncertainties that could cause actual results to differ materially from those
projected, including, but not limited to, uncertainties relating to
technologies, product development, manufacturing, market acceptance, cost and
pricing of DNAPrint's products, dependence on collaborations and partners,
regulatory approvals, competition, intellectual property of others, and patent
protection and litigation. DNAPrint genomics, Inc. expressly disclaims any
obligation or undertaking to release publicly any updates or revisions to any
forward-looking statements contained herein to reflect any change in
DNAPrint's expectations with regard thereto or any change in events,
conditions, or circumstances on which any such statements are based.
Media and Press Contacts
Richard Gabriel
DNAPrint genomics, Inc.
CEO/President
+1-941-366-3400
SOURCE DNAPrint genomics, Inc.
-0- 05/10/2004
/CONTACT: Richard Gabriel, CEO - President, DNAPrint genomics, Inc.,
+1-941-366-3400/
/Web site: http://www.dnaprint.com
http://www.familytreelegends.com
http://www.ancestrybydna.com/strorder.asp /
(DNAP)
CO: DNAPrint genomics, Inc.; Pearl Street Software
ST: Florida
IN: MTC OTC CPR STW
SU: PDT
*** end of story ***
(PR NEWSWIRE) DNAPrint Upgrades DNAWitness For Use in the War on Terror
DNAPrint Upgrades DNAWitness For Use in the War on Terror
SARASOTA, Fla., April 30 /PRNewswire-FirstCall/ -- DNAPrint genomics (OTC
Bulletin Board: DNAP) of Sarasota, FL announces that the forensics version of
its innovative whole-genome test for individual ancestry admixture (DNAWITNESS
2.0) has been upgraded for enhanced utility in the international war on
terrorism.
The original DNAWitness(TM) 2.0 test was capable of reporting the
percentage of "European," "western sub-Saharan African," "East Asian" and
"Native American" admixture from a crime scene sample, where the colloquial
terms in quotes represent ancestry traced to four of the major phlyogeographic
clades that constitute the human family tree. The upgraded version of the
test, DNAWitness(TM) 2.5 is capable of doing the same, but in addition can
determine whether a donor of primarily European admixture is of continental
European, Middle Eastern or Indo-Pakistani origin, or whether an East Asian's
major ethnic affiliation is Northern (Chinese/Japanese), Central Asian or
South East Asian.
In its ability to effectively resolve between continental European, Middle
Eastern and Indo-Pakistani origin for a crime scene sample, the upgraded
DNAWitness(TM) 2.5 has unprecedented utility for use in the international war
on terrorism.
The DNAWitness(TM) 2.5 genome test is designed to allow forensics
investigators to employ objective science, empiricism and statistical analysis
in the reconstruction of a physical profile or fuzzy photo from DNA left at a
crime scene. DNAPrint has filed both domestic and international PCT patent
applications on many of the most useful markers, database systems and software
algorithms necessary for this purpose. The new technology added to
DNAWitness(TM) makes the product the first scientific instrument ever capable
of measuring within-continent (i.e. ethnic) ancestry by reading across the
entire genome. Prior to the development of DNAWitness(TM) 2.5, a small number
of academic researchers were capable of making inferences on ethnicity from Y
and mtDNA haplogroups, but these sequences reflect merely 2 of the 23 chapters
(chromosomes) in every persons genome and from those short chapters, it is
currently not possible to determine whether the ethnic affiliation of an
individual human being is dominant or minor. Similarly, using CODIS STR (Short
Tandem Repeat) loci, typically used for Forensic identity testing for the
inference of ethnicity is notoriously not reliable and potentially misleading,
since these genetic markers are not Ancestry Informative, and in fact are the
opposite of Ancestry Informative, having been selected from the genome based
on their lack of inter-population diversity. DNAWitness 2.5 has eliminated the
confusion and is very accurate in predicting the genetic heritage of a donor's
DNA.
About DNAPrint genomics, Inc.
DNAPrint genomics Inc. uses proprietary human genome research methods to
develop genomic-based services and products. The Company introduced
ANCESTRYbyDNA(TM) in the consumer market and DNAWitness(TM) in the forensic
market in 2003. DNAPrint is developing products in the pharmacogenomic market
and has a disease gene discovery program. The Company is traded on the Nasdaq
OTC Bulletin Board under the ticker symbol: DNAP. For more information about
the company, please visit www.dnaprint.com.
All statements in this press release that are not historical are forward-
looking statements within the meaning of Section 21E of the Securities
Exchange Act as amended. Such statements are subject to risks and
uncertainties that could cause actual results to differ materially from those
projected, including, but not limited to, uncertainties relating to
technologies, product development, manufacturing, market acceptance, cost and
pricing of DNAPrint's products, dependence on collaborations and partners,
regulatory approvals, competition, intellectual property of others, and patent
protection and litigation. DNAPrint genomics, Inc. expressly disclaims any
obligation or undertaking to release publicly any updates or revisions to any
forward-looking statements contained herein to reflect any change in
DNAPrint's expectations with regard thereto or any change in events,
conditions, or circumstances on which any such statements are based.
Media and Press Contacts
Richard Gabriel
DNAPrint genomics, Inc.
CEO/President
+1-941-366-3400
SOURCE DNAPrint genomics, Inc.
-0- 04/30/2004
/CONTACT: Richard Gabriel, CEO/President of DNAPrint Genomics, Inc., +1-
941-366-3400/
/Web site: http://www.dnaprint.com/
(DNAP)
CO: DNAPrint genomics, Inc.
ST: Florida
IN: MTC BIO ARO
SU: PDT
*** end of story ***
Quiet but quick LOL
(PR NEWSWIRE) DNAPrint's DNAWitness(TM) Technology Tightens Net on UK Rapist
DNAPrint's DNAWitness(TM) Technology Tightens Net on UK Rapist
SARASOTA, Fla., April 28 /PRNewswire-FirstCall/ -- DNAPrint genomics
(OTC Bulletin Board: DNAP) (DNAP) of Sarasota, FL confirmed that the United
Kingdom's New Scotland Yard and London's Metropolitan Police have
strategically employed its proprietary DNAWitness(TM) test.
The genomics test was used as part of a 12-year investigation focused on a
serial rapist who has committed over 80 attacks on mostly elderly victims.
The case is still unresolved. Ongoing research at DNAPrint(TM) has resulted
in a substantial enhancement of the power of DNAWitness(TM) as an
investigative tool.
Metropolitan Police Detectives said the test gave them their biggest lead
yet in a 12-year hunt for a serial sex attacker who preys on elderly women.
"After 12 years we feel this is a major breakthrough and are confident that
the new DNA results should lead us to the suspect or even his relatives,"
Detective Superintendent Simon Morgan of London's Metropolitan Police told
reporters on Tuesday.
For the full story see: http://uk.news.yahoo.com/040427/325/es4k2.html.
"Earlier this year we announced our new product, DNAWitness(TM), and since
then the product has been used on nearly 40 cases," said Richard Gabriel, CEO
and President of DNAPrint(TM). "The fact is that we are not permitted to
discuss any of these cases with the media, and so the importance of our
contributions often goes unnoticed by the public. When a particular group
such as the London Metropolitan Police and New Scotland Yard give us
permission to discuss our involvement, it should signal to the rest of the law
enforcement community, worldwide, that DNAWitness(TM) is a viable source of
new information on crimes," he said.
As a presumptive test, DNAWitness(TM) can be used on other crimes such as
burglary, robbery, assault, battery, murder and other felony crimes -- as long
as a biological specimen (such as blood, semen, saliva or hair) was left at
the scene. Florida had 26,000 aggravated rapes last year, and samples were
collected from most every one, but the samples sit on shelves for years when
they could be used to paint profiles of the rapists. DNAPrint(TM) would like
every patrol car in the near future to carry a DNAWitness(TM) crime scene kit.
Mr. Gabriel continued, "Patterns could be uncovered, eye-witness leads
prioritized, and social and geographical links established that might lead to
apprehensions, and prevent further harm to unsuspecting individuals. However,
most states do not use their resources to even process these kits for standard
(low tech) DNA testing, which is always the first DNA test performed. Those
that do use our technology in the U.S. are often prevented from publicizing
their profiles. This is unfortunate because publication of the profile often
results in new leads. We have learned that there are countless frustrated
and hard working investigators that want to use our new technology but don't
have the funds available to them, and who want to publicize their profiles but
cannot. Law enforcement and prosecutors now have additional tools to hunt
down and jail these criminals, and it would be in all of our interests that
they be more widely used. DNAWitness(TM) is not a panacea, but it is another
tool, and it's available now. And that new tool, coupled with good old
fashioned detective work, will help get repeat offenders off our streets."
About DNAPrint genomics, Inc.
DNAPrint genomics Inc. uses proprietary human genome research methods to
develop genomic-based services and products. The Company introduced
ANCESTRYbyDNA(TM) in the consumer market and DNAWitness(TM) in the forensic
market in 2003. DNAPrint(TM) is developing products in the pharmacogenomic
market and has a disease gene discovery program. The Company is traded on the
Nasdaq OTC Bulletin Board under the ticker symbol: DNAP. For more information
about the company, please visit www.dnaprint.com.
DNAWitness(TM) is a DNAPrint genomics, Inc. proprietary product and FREE
collection kits can be ordered from Lynn Peavey - crime scene supplies
Forensic Innovations for Law Enforcement and Laboratories 1-800-255-6499,
800-255-6499 (C) Copyright 2003 Lynn Peavey Company.
http://www.lynnpeavey.com/ or from DNAPrint(TM) directly
1-941-366-3400 http://www.dnaprint.com.
All statements in this press release that are not historical are forward-
looking statements within the meaning of Section 21E of the Securities
Exchange Act as amended. Such statements are subject to risks and
uncertainties that could cause actual results to differ materially from those
projected, including, but not limited to, uncertainties relating to
technologies, product development, manufacturing, market acceptance, cost and
pricing of DNAPrint's products, dependence on collaborations and partners,
regulatory approvals, competition, intellectual property of others, and patent
protection and litigation. DNAPrint genomics, Inc. expressly disclaims any
obligation or undertaking to release publicly any updates or revisions to any
forward-looking statements contained herein to reflect any change in
DNAPrint's expectations with regard thereto or any change in events,
conditions, or circumstances on which any such statements are based.
Media and Press Contacts
Richard Gabriel
DNAPrint Genomics, Inc.CEO/President(941) 366-3400
SOURCE DNAPrint Genomics, Inc.
-0- 04/28/2004
/CONTACT: Richard Gabriel, CEO and President, DNAPrint Genomics,
+1-941-366-3400/
/Web site: http://www.dnaprint.com /
(DNAP)
CO: DNAPrint Genomics, Inc.
ST: Florida
IN: MTC OTC
SU:
*** end of story ***
(PR NEWSWIRE) DNAPrint(TM) Invited to Present at the National District Attorney
Association Board of Directors Meeting
DNAPrint(TM) Invited to Present at the National District Attorneys Association B
ard of Directors Meeting
SARASOTA, Fla., March 18 /PRNewswire/ -- DNAPrint(TM) genomics, Inc.
("DNAPrint" or the "Company") has been invited to present its flagship
product, DNAWitness(TM), at the National District Attorneys Association Board
of Directors Meeting to be held March 18-20, 2004 at the Radisson Bahia Mar in
Ft. Lauderdale, Florida. The company's Technical Director of Forensics, Zach
Gaskin, will discuss how DNAWitness(TM) can aid in investigations and will
describe recent cases in which the technology has been applied. DNAWitness(TM)
is an advanced presumptive DNA test that gives an investigator a reasonably
good eyewitness at the crime scene by using the genetic code of the donor. The
test determines the Biogeographical Ancestry (BGA) of an individual giving the
percentages of East Asian, Native American, European, and Sub-Saharan African.
"Meetings such as this are helping us reach into all areas of the justice
system. Primarily, DNAWitness(TM) cases come from the crime labs, detectives
and prosecutors, so it is important to provide each of these areas with
information about the test," said Zach Gaskin, Technical Director of Forensics
with DNAPrint(TM). "Every agency in the U.S. has at least one case, if not
more, where this technology can, and should, be applied. Educating people
about DNAWitness(TM) is the first step to helping solve these crimes. Imagine
for a second if a fuzzy photo ID was left at each crime scene. That's what
this test can do for an investigation."
"Our long-term goal with this technology is to bring all crime scene
donors' DNA to the detectives. The fuzzy photos that we provide will help
investigators sort through the hundreds, sometime thousands, of bits of
information, helping them and the prosecutors determine who is and who is not
likely to be a suspect in a crime," said Richard Gabriel, the Company's CEO
and President. "DNAWitness(TM) is a flagship product that provides stunning
results that can help detectives and prosecutors by matching donor crime scene
DNA to eyewitness reports. That's just one example of its application, and
because it is a presumptive test, it can be used wherever DNA is found at a
crime scene. The test kit used to collect the evidence is free from
DNAPrint(TM) genomics and through the Lynn Peavey Company catalog. We perform
all of our analysis under the strictest confidentiality and highest quality
control and quality assurance. We are delighted and honored to be selected as
a guest speaker at the National District Attorneys Association Board of
Directors Meeting."
About DNAPrint(TM) genomics, Inc.
DNAPrint(TM) genomics, Inc. was founded by a team of scientists with
research and commercial experience in high-level mathematical modeling,
programming and molecular genetics. The DNAWitness(TM) and the
ANCESTRYbyDNA(TM) analysis is a direct result of focused research by the DNAP
research and development team.
In addition, using proprietary human genome research methods, the Company
develops pharma-predictive tests for matching patients with drugs based on
their genetic constitution, discovers disease genes for the development of new
drugs and develops new forensic genomics and consumer genomics testing
products. The Company is traded on the Nasdaq OTC Bulletin Board under the
ticker symbol: DNAP. For more information about the company, please visit
www.dnaprint.com.
For more information on our genealogical DNA-derived test,
ANCESTRYbyDNA(TM) 2.5, visit us on line at www.ancestrybydna.com helping
everyone to understand their genetic heritage.
All statements in this press release that are not historical and are
forward-looking statements within the meaning of Section 21E of the Securities
Exchange Act as amended. Such statements are subject to risks and
uncertainties that could cause actual results to differ materially from those
projected, including, but not limited to, uncertainties relating to
technologies, product development, manufacturing, market acceptance, cost and
pricing of DNAPrint's(TM) products, dependence on collaborations and partners,
regulatory approvals, competition, intellectual property of others, and patent
protection and litigation. DNAPrint(TM) genomics, Inc. expressly disclaims any
obligation or undertaking to release publicly any updates or revisions to any
forward-looking statements contained herein to reflect any change in
DNAPrint's(TM) expectations with regard thereto or any change in events,
conditions, or circumstances on which any such statements are based.
Media and Press Contacts
Richard Gabriel
DNAPrint(TM) genomics, Inc.
CEO/President
(941) 366-3400
SOURCE DNAPrint genomics, Inc.
-0- 03/18/2004
/CONTACT: Richard Gabriel, CEO - President, DNAPrint(TM) genomics,
+1-941-366-3400/
/Web site: http://www.dnaprint.com
http://www.ancestrybydna.com /
(DNAP)
CO: DNAPrint genomics, Inc.; National District Attorneys Association
ST: Florida
IN: MTC OTC
SU:
*** end of story ***
I use Mytrack.com, and it alerts me on all news of the stocks I am tracking.
(PR NEWSWIRE) DNAPrint(TM) Participates in the TBTF and BioFlorida Tampa Bay Pa
tnering Conference Thursday, April 1, 2004
DNAPrint(TM) Participates in the TBTF and BioFlorida Tampa Bay Partnering Confer
nce Thursday, April 1, 2004
SARASOTA, Fla., March 17 /PRNewswire-FirstCall/ -- DNAPrint's CEO and
President is presenting at the combined Tampa Bay Technology Forum and
BioFlorida Tampa Bay partnering conference on April 1, 2004 at the Hyatt
Sarasota, 1000 Blvd. of the Arts, Sarasota, Florida. The presentation will
include a description of DNAPrint(TM)'s technology and market applications.
The presentation will highlight the four market segments in which DNAPrint(TM)
applies its proprietary Single Nucleotide Polymorphism (SNP) screening
technology: 1) genealogy; featuring its latest released product
ANCESTRYbyDNA(TM) 2.5 used by genealogists and families to help understand
their genetic heritage; 2) forensics; featuring its flagship product
DNAWitness(TM) 2.0, which was introduced and first used in the first quarter
of 2003 and has since helped detectives and investigators in two high-profile
cases, the Louisiana serial killer case (2003) and the Concord, California
case; 3) pharmacogenomics; the company is working with a Florida institution
to advance its technology (known as Ovanome(TM)) and to combine its technology
with other genetic methods to help reduce the risk of cancer treatment; and 4)
contract genotyping; the company has developed a strong reputation as a
reliable and cost-effective contract genotyping service and continues to
supply medical centers and universities with this service.
"We see the forum as a means to advance our company and improve
shareholder value through partnering opportunities that might present
themselves at this conference," said Richard Gabriel, CEO and President of
DNAPrint(TM) genomics, Inc. "Over the last year we have been relatively quiet.
We have spent this time reorganizing the company and advancing our
technologies. We are seeking partners in all three commercial areas,
genealogy, forensics and pharmacogenomics, and that could include partners in
a variety of structures. We have just finished an $8.0 million financing
round, and the proceeds from that transaction have been flowing into the
company at a steady rate. This is the fuel that we need to build the business
and advance the technology, and we are doing that."
"The company's senior management will continue to explore all
opportunities, and we believe these partnering forums are a great vehicle for
allowing companies to exchange ideas and seek new opportunities," said Hector
Gomez, MD, PhD, Chairman of the Board and Chief Medical Officer. "Our joining
BioFlorida and being involved with the Sarasota business community is another
step in advancing our technology and company," he said.
"Sarasota and the Tampa Bay area are a rapidly emerging biotechnology
center, and we were one of the first life-science companies to start up in
Sarasota -- well, certainly one of the first genetics companies," said Tony
Frudakis, PhD. "We're excited about the partnering opportunities that might
exist in our own backyard."
About DNAPrint(TM) genomics, Inc.
DNAPrint(TM) genomics, Inc. was founded by a team of scientists with
research and commercial experience in high-level mathematical modeling,
programming and molecular genetics. The DNAWitness(TM) and the
ANCESTRYbyDNA(TM) analysis is a direct result of focused research by the DNAP
research and development team.
In addition, using proprietary human genome research methods, the Company
develops pharma-predictive tests for matching patients with drugs based on
their genetic constitution, discovers disease genes for the development of new
drugs and develops new forensic genomics and consumer genomics testing
products. The Company is traded on the Nasdaq OTC Bulletin Board under the
ticker symbol: DNAP. For more information about the company, please visit
www.dnaprint.com.
For more information on our genealogical DNA-derived test,
ANCESTRYbyDNA(TM) 2.5, visit us on line at www.ancestrybydna.com helping
everyone to understand their genetic heritage.
All statements in this press release that are not historical and are
forward-looking statements within the meaning of Section 21E of the Securities
Exchange Act as amended. Such statements are subject to risks and
uncertainties that could cause actual results to differ materially from those
projected, including, but not limited to, uncertainties relating to
technologies, product development, manufacturing, market acceptance, cost and
pricing of DNAPrint's(TM) products, dependence on collaborations and partners,
regulatory approvals, competition, intellectual property of others, and patent
protection and litigation. DNAPrint(TM) genomics, Inc. expressly disclaims any
obligation or undertaking to release publicly any updates or revisions to any
forward-looking statements contained herein to reflect any change in
DNAPrint's(TM) expectations with regard thereto or any change in events,
conditions, or circumstances on which any such statements are based.
Media and Press Contacts
Richard Gabriel
DNAPrint(TM) genomics, Inc.
CEO/President
(941) 366-3400
SOURCE DNAPrint(TM) genomics, Inc.
-0- 03/17/2004
/CONTACT: Richard Gabriel, CEO - President, DNAPrint(TM) genomics,
+1-941-366-3400/
/Web site: http://www.dnaprint.com
http://www.ancestrybydna.com /
(DNAP)
CO: DNAPrint(TM) genomics, Inc.
ST: Florida
IN: MTC OTC
SU:
*** end of story ***
(PR NEWSWIRE) DNAPrint Secures a Distributor for its DNA Witness(TM) Test to Be
ter Serve Law Enforcement
DNAPrint Secures a Distributor for its DNA Witness(TM) Test to Better Serve Law
nforcement
SARASOTA, Fla., Feb. 17 /PRNewswire-FirstCall/ -- DNAPrint genomics, Inc.
(DNAPrint or the "Company") has teamed up with Lynn Peavey Company of Kansas
City to advance the use of DNA Witness(TM) in the law enforcement community.
Lynn Peavey is the leader in providing law enforcement with forensic
innovations for use at the crime scene and in the laboratory. Lynn Peavey
reaches over 17,000 law enforcement agencies across the country. DNA
Witness(TM) is an advanced presumptive DNA test that determines the
Biogeographical Ancestry of an individual with no other information but the
person's genetic code.
"This is a great opportunity to give our customer base another shot at
solving the mystery of committed crimes...because, often they have no idea of
which direction to go in an investigation once the leads have not produced a
suspect," said Doug Peavey, President of Lynn Peavey Company.
"This partnership will increase our presence in the law enforcement
community," said Zach Gaskin, Technical Director of Forensics with DNAPrint.
"This is the opportunity that we needed to get the DNA Witness test into the
hands of the people who need it most. There are over 70,000 unsolved cases in
the National DNA Index System, and many of them could benefit from this
testing. We are excited about the distributorship because the Lynn Peavey
Company is a well-respected supplier in the law enforcement community and
already does business with most of the agencies in the U.S."
"DNAWitness, our flagship product for the detective is a presumptive test,
and Doug Peavey's company is well positioned to offer this test to the crime
lab and detective community," said Richard Gabriel, CEO and President. "We
continue to invest in our technology for the forensics market because the
crime numbers are staggering. Our laboratory can process thousands of samples
per day but getting the law enforcement community to use our product requires
the help and support of Lynn Peavey Company. Doug's company sends catalogs all
over the world, and we are prepared to help detectives solve crimes no matter
where they occur. In the state of Florida, there were over 26,000 aggravated
sexual assaults, extrapolate that over all the states, then Europe, then South
America ... these are staggering statistics." He concluded, "We are teaming up
with Lynn Peavey Company and offering training seminars on how, where, why,
when to use DNAWitness. The kit itself is free but if you don't know how to
use it and when and why and what it tells you, then it doesn't mean much to a
detective. Our goal is to have detectives, medical examiners and crime labs
use our service to help them catch criminals, identify unknown remains and
solve cold cases. We are another tool in their kit."
"DNAWitness has been a powerful instrument in testing crime scene DNA left
by the donor," said Tony Frudakis, Chief Scientific Officer and Founder of
DNAPrint genomics, Inc. "We continue to add features to the product and we
expect that soon, detectives will have another new feature, eye color; then
later on skin shade, maybe height and other descriptors. We want every
criminal to know that when they commit a crime, they left behind a fuzzy
photo, a blurry driver's license with no name on it. Detectives are really
good at working with seemingly disconnected and sparse evidence, and adding
the name to the fuzzy photo is in their realm of expertise. This presumptive
test can be used on all crimes, not just the murders but the sexual assaults,
burglaries, car thefts, robberies, and many other pieces of evidence. Law
enforcement officers across the world know that crimes such as these can and
often do lead to the more violent crimes, murder being the worst."
DNAPrint genomics, Inc. and Lynn Peavey Company are attending the 56th
Annual American Academy of Forensic Science Meeting in Dallas on February 16-
21, 2004 where Zach Gaskin is presenting on the use of DNA Witness in the
Louisiana Serial Killer Case. Their tradeshow booth numbers are 517 for
DNAPrint and 416-417 for Lynn Peavey Company.
About DNAPrint genomics, Inc.
DNAPrint(TM) genomics, Inc., ("DNAPrint (TM)" or the "Company"), is a
genomics science company focused on the sale of proprietary genetic testing
products and services. The Company's core technologies for efficiently
targeting single nucleotide polymorphisms ("SNPs") enable it to provide
predictive genetic tests at a significant cost advantage over its competitors.
The Company has identified and patented the maps of certain SNPs with wide
commercial applications called Ancestry Informative Markers ("AIMS"). The
Company believes that AIMs are the key for unlocking the relationship between
common variants and common anthropometric, disease and drug response traits.
Effectively mapping disease and drug response sequences could lead to the
development of clinical classifiers for improving drug development,
personalizing drug use and empowering forensics investigations. The Company's
patented AIMs are integral to the Company's strategy of offering DNA tests
that provide valuable predictive results, including a person's physical
characteristics, Biogeographical Ancestry ("BGA"), and predisposition to
respond to certain pharmaceutical drugs. The Company's tests target four
distinct markets -- forensics, consumer, pharmacogenomics (predicting drug
response) and outsourced screening services. The Company is traded on the
Nasdaq OTC Bulletin Board under the ticker symbol: DNAP. For more information
about the company, please visit www.dnaprint.com.
All statements in this press release that are not historical are forward-
looking statements within the meaning of Section 21E of the Securities
Exchange Act as amended. Such statements are subject to risks and
uncertainties that could cause actual results to differ materially from those
projected, including, but not limited to, uncertainties relating to
technologies, product development, manufacturing, market acceptance, cost and
pricing of DNAPrint's products, dependence on collaborations and partners,
regulatory approvals, competition, intellectual property of others, and patent
protection and litigation. DNAPrint genomics, Inc. expressly disclaims any
obligation or undertaking to release publicly any updates or revisions to any
forward-looking statements contained herein to reflect any change in
DNAPrint's expectations with regard thereto or any change in events,
conditions, or circumstances on which any such statements are based.
Media and Press Contacts
Richard Gabriel
CEO/President
DNAPrint Genomics, Inc.
941-366-3400
SOURCE DNAPrint Genomics, Inc.
-0- 02/17/2004
/CONTACT: Richard Gabriel, CEO and President, DNAPrint Genomics, Inc.,
+1-941-366-3400/
/Web site: http://www.dnaprint.com/
(DNAP)
CO: DNAPrint Genomics, Inc.; Lynn Peavey Company
ST: Florida, Missouri
IN: MTC OTC
SU: JVN
*** end of story ***
(PR NEWSWIRE) DNAPrint(TM) Launches ANCESTRYbyDNA(TM) 2.5, The Most Powerful BG
Admixture Test Ever Developed
DNAPrint(TM) Launches ANCESTRYbyDNA(TM) 2.5, The Most Powerful BGA Admixture Tes
Ever Developed
SARASOTA, Fla., Jan. 27 /PRNewswire/ -- DNAPrint(TM) genomics, Inc.
(OTC Bulletin Board: DNAP)(DNAPrint(TM) or the "Company") today introduced a
new version of its popular ANCESTRYbyDNA(TM) 2.0 test for the genetic
determination of BioGeographical Ancestry (BGA) admixture.
The new test, "ANCESTRYbyDNA(TM) 2.5" provides increased power and
enhanced sensitivity for genealogists because it is powered by 175 rather than
71 Ancestry Informative Markers (AIMs). The test is an augmented version of
ANCESTRYbyDNA(TM) 2.0; 104 new AIMs were added to the core set of 71 used in
the old test. Like the 2.0 version, ANCESTRYbyDNA(TM) 2.5 provides a
customer's proportional Native American, East Asian, Indo-European, and West
Sub-Saharan African BGA, but the increased number of markers allow for more
sensitive and accurate determinations of low levels of admixture (such as that
which may have been contributed by a single great grandparent). The enhanced
sensitivity and efficiency allowed DNAPrint(TM) to also upgrade the
presentation of results for the 2.5 version.
The human genome has millions of markers, or genetic variations, but only
1-2% of these markers (0.002% of the genome) are ancestry informative.
Because the AIMs measured by the test are among the genomes best, and due to
the enhanced coverage of 8 AIMs per average chromosome, ANCESTRYbyDNA(TM) 2.5
represents the most powerful test of its kind ever developed. The new test
sells for $219 per test. Customers who purchased the 2.0 version will receive
an upgrade to 2.5 at a reduced rate of $158.
The new test has been added to the www.ancestrybydna.com website. The
Company is typing samples from discrete populations, such as groups of
individuals who identify with a single ethnic or tribal group. The new
website provides data from simulations that address the accuracy and precision
of the ANCESTRYbyDNA(TM) tests. New data will be added to the website
continuously as it is produced, allowing customers an empirical frame of
reference for interpreting their results.
About DNAPrint(TM) genomics, Inc.
DNAPrint(TM) genomics, Inc., ("DNAPrint(TM)" or the "Company"), is a
genomics science company focused on the sale of proprietary genetic testing
products and services. The Company's core technologies for efficiently
targeting single nucleotide polymorphisms ("SNPs") enable it to provide
predictive genetic tests at a significant cost advantage over its competitors.
The Company has identified and patented the maps of certain SNPs with wide
commercial applications called Ancestry Informative Markers ("AIMS"). The
Company believes that AIMs are the key for unlocking the relationship between
common variants and common anthropometric, disease and drug response traits.
Effectively mapping disease and drug response sequences could lead to the
development of clinical classifiers for improving drug development,
personalizing drug use and empowering forensics investigations. The Company's
patented AIMs are integral to the Company's strategy of offering DNA tests
that provide valuable predictive results, including a person's physical
characteristics, Biogeographical Ancestry ("BGA"), and predisposition to
respond to certain pharmaceutical drugs. The Company's tests target four
distinct markets -- forensics, consumer, pharmacogenomics (predicting drug
response) and outsourced screening services. The Company is traded on the
Nasdaq OTC Bulletin Board under the ticker symbol: DNAP. For more information
about the company, please visit www.dnaprint.com.
All statements in this press release that are not historical are forward-
looking statements within the meaning of Section 21E of the Securities
Exchange Act as amended. Such statements are subject to risks and
uncertainties that could cause actual results to differ materially from those
projected, including, but not limited to, uncertainties relating to
technologies, product development, manufacturing, market acceptance, cost and
pricing of DNAPrint's(TM) products, dependence on collaborations and partners,
regulatory approvals, competition, intellectual property of others, and patent
protection and litigation. DNAPrint(TM) genomics, Inc. expressly disclaims any
obligation or undertaking to release publicly any updates or revisions to any
forward-looking statements contained herein to reflect any change in
DNAPrint's(TM) expectations with regard thereto or any change in events,
conditions, or circumstances on which any such statements are based.
Media and Press Contacts
Richard Gabriel
DNAPrint(TM) genomics, Inc.
CEO/President
(941) 366-3400
SOURCE DNAPrint(TM) genomics, Inc.
-0- 01/27/2004
/CONTACT: Richard Gabriel, CEO and President, DNAPrint(TM) genomics,
Inc.,
+1-941-366-3400/
/Web site: http://www.dnaprint.com
http://www.ancestrybydna.com /
(DNAP)
CO: DNAPrint(TM) genomics, Inc.
ST: Florida
IN: MTC OTC
SU: PDT
*** end of story ***
news from another board!
read about shorting..
NEW YORK (Dow Jones)--Taking most market participants by surprise, the
National Association of Securities Dealers has drastically tightened one of
its rules governing short selling.
Known as affirmative determination, the NASD rule stipulates that brokers
and dealers engaged in a short sale transaction must make sure that shares
can be delivered by settlement time, three days later.
"We closed a loophole," said Steve Luparello, executive vice president of
Market Regulation at NASD.
Until now, non-NASD members, like specialists, option markets and foreign
brokers, weren't covered under the affirmative determination rule. That
means that non-NASD members didn't have to represent to the NASD broker
through which they conducted a short sale order that they would be able to
deliver the stock by settlement date.
A short seller typically borrows stock from a broker to sell it into the
market, betting that the share price will fall so that he can buy the stock
back at a lower price and pocket the difference.
The amended NASD affirmative determination rule, which was recently approved
by the Securities and Exchange Commission, will particularly affect short
sales conducted through foreign brokers, most specifically Canadian brokers
which have often been used by investors to sell short the stock of small
U.S. companies trading on the Over-the-counter Bulletin Board or OTCBB.
Because it's often impossible to borrow the shares of companies trading on
the OTCBB, investors and hedge funds looking to take negative bets on these
often-overvalued development-stage companies have traditionally been trading
through Canada where it's not required to borrow stock before selling it
short. The practice is known as naked shorting.
That trading avenue has now been effectively closed.
The new NASD rule doesn't cover Canadian brokers, since most are not members
of the association, instead it makes it the responsibility of U.S. brokers
trading with non-members to make sure that their counterparts will be able
to settle a transaction before completing a short sale.
"It's part of (a broker's) supervisory responsibilities," NASD's Luparello
said, adding that a non-member's previous failures to deliver should be a
good indication of whether or not it will in fact be able to complete the
transaction by the settlement date.
Market makers engaged in bone fide market making activities will continue to
be exempt from affirmative determination.
Luparello said that, unlike a parallel SEC initiative to tighten short
selling rules on the small-cap markets, the new NASD rules did not originate
from worries over mounting failures to deliver stock into the national
clearing system. But Luparello said the amended NASD rule fits nicely with
the new short selling regulations now under consideration by the SEC.
"I think it addresses a gap and (shows) that we, like the SEC, are looking
at a variety of things in this area," Luparello said.
The NASD proposal was first submitted to the SEC in November 2001, well
before alleged abuses of naked shorting became the focal point of a campaign
lead by some OTCBB companies in the U.S that say they have been victimized
by the practice.
While some investors argue that short sellers provide a needed service to
the markets, others have called for the complete abolition of short selling
because of the undue pressure its puts on the shares of companies.
While market participants in the U.S. and abroad are well aware of the new
short selling regulations being put forward by the SEC, known as Regulation
SHO, most said they knew nothing of the NASD's plan before it became final.
"It's taken us by surprise," said Richard Thomas, head of compliance at
Canadian brokerage firm Pacific International.
Although separate from it, the amended NASD rule fits tightly within the
SEC's SHO which is now under review by the SEC staff after a period during
which market participants were invited to comment on it.
As it stands, the new SEC short selling rules will make it easier to short
large-cap stocks since they would do away with the "uptick" rule, which bans
short selling on a stock when the price is falling.
But it when it comes to the small-cap markets, where it's often impossible
to borrow stock, the impact of SHO will be the opposite, making it harder to
short sale stock.
The new SEC rule sets a predetermined level of so-called clearing fails -
cases in which a broker or investor cannot deliver stock within two days
after settlement - which will trigger a 90-day blackout whereby the customer
will not be allowed to short sell that security. That 90-day exemption would
affect trading of U.S. securities in and outside the U.S.
The new NASD affirmative determination rule will take effect on Feb. 20.
BS, you posted that on RB with your redemptionman_0 alias.
Very interesting post from RB
By: A57TBird
22 Dec 2003, 08:15 PM EST
Msg. 289016 of 289016
Jump to msg. #
TonyToX ? ADMIXMAP Concerns Answered...
Last week you challenged Ming to perform a Google search on ADMIXMAP and to pay particular attention to the first hit that showed up. I decided to do the same. The first link was to the London School of Hygiene & Tropical Medicine. At the bottom of this article were listed two points of contact, so I decided to e-mail one of them to voice your concern about DNAP?s claim to the term ADMIXMAP. The following is the reply that I received. I took out the name of the individual who replied, but if you go to that link I think you will figure out who it was. I found the reply to be pretty enlightening concerning DNAP, Dr. Mark Shriver, and their common associates. I wanted to post this last week, but I also wanted the individual to have the opportunity to let me know whether or not he wanted me to do so. Anyway?
-----------------------------------------------------------
http://www.lshtm.ac.uk/eu/genetics/admix.html
Dear Mr Xxxxxx
By chance, it seems that DNAPrint chose the name ADMIXMAP for its method of measuring admixture using a panel of specially-chosen markers at the same time as we, independently, chose the name ADMIXMAP for a statistical analysis program that we have developed to model admixture and localize genes underlying ethnic variation in disease risk.
A happy result of this coincidence was that DNAPrint and our research group were able to find each other and to identifiy possibilities for working together. Our work on developing statistical and computational methods is complementary to DNAPrint's work on the discovery of ancestry-informative markers and on typing these markers with ith phenotype data. We are now working closely with Dr Tony Frudakis at DNAPrint to test our statistical methods for predicting phenotype from marker data, using data supplied by DNAPrint. We are now discussing plans for a formal collaboration in which we will provide specialized statistical support to DNAPrint, provide DNAPrint with DNA samples and clinical data that we have collected, and work together to find genes underlying ethnic variation in disease risk. We believe that combining our statistical methods with DNAPrint's proprietary approach can greatly increase its power and flexibility.
We're not too bothered about the name ADMIXMAP - we could easily change the name of our program if difficulties arise.
Xxxx Xxxxxxxx
Department of Epidemiology and Population Health
London School of Hygiene & Tropical Medicine
Keppel Street, WC1E 7HT, UK
Tel: +44 (0)20 7927 2312
Fax: +44 (0)20 7580 6897
Email: xxxx.xxxxxxx@lshtm.ac.uk
(Voluntary Disclosure: Position- Long; ST Rating- Strong Buy; LT Rating- Strong Buy)
(PR NEWSWIRE) DNAPrint(TM) genomics, Inc. Secures Up To $8 Million In Financing
From La Jolla Cove Investors
DNAPrint(TM) genomics, Inc. Secures Up To $8 Million In Financing From La Jolla
ove Investors
SARASOTA, Fla., Dec. 3 /PRNewswire-FirstCall/ -- DNAPrint(TM) genomics,
Inc. (OTC Bulletin Board: DNAP) has secured a commitment from La Jolla Cove
Investors, Inc. to invest up to $8 million in the company over approximately
the next two years. The transaction involves a debenture convertible into
common stock and warrants to purchase common stock, resulting in a commitment
of $400,000 per month over a twenty month period. The purchase price is based
on the trading price of the company's stock, and the funding will begin after
the company registers the common stock that the company will issue in the
transaction. DNAPrint(TM) anticipates that the transaction will provide it
with equity to build the business.
"We are extremely excited about the prospects for DNAPrint(TM) now that we
have established a reliable source of capital for the foreseeable future,"
said Richard Gabriel, CEO and President of DNAPrint(TM). "This financing, once
the registration process at the SEC is completed, should allow management to
build shareholder value. We expect to be able to increase our revenues by
hiring personnel, expanding operations and aggressively pursuing business
opportunities in the forensics, pharmacogenomics and consumer products arena,"
said Mr. Gabriel.
"This investment starts a new phase of development for the company that
will include the expansion of our Clinical Pharmacogenomics Program.
DNAPrint(TM) is now poised to make a significant contribution to the upcoming
era of personalized medicine," said Hector J. Gomez, MD, PhD, and Chairman of
the Company's Board.
Athena Capital Partners, Inc. in Tampa, Florida was the private merchant
bank that brought La Jolla Cove Investors and DNAPrint(TM) together. "This is
the kind of deal that really helps a company like DNAPrint(TM) grow," said
Kevin Cimino, Managing Director and Principal at Athena.
"We are very pleased with the outcome of our arrangement with Athena
Capital, and we look forward to our new relationship with La Jolla Cove. This
transaction recognizes the value of companies like DNAPrint -- companies that
are not afraid to take scientific risks, companies that develop technologies
that are neglected or unforeseen by others and companies that devote their
efforts to rapidly commercializing products for underserved markets," said
Tony Frudakis, Founder and CSO.
Monica Tamborini, CFO and COO of DNAPrint(TM), commented, "We believe
DNAPrint(TM) has a bright future, and this important step will help the
management achieve its objectives. Our goal and our mission are to increase
shareholder value through real growth."
About DNAPrint(TM) genomics, Inc.
DNAPrint genomics, Inc. was founded by a team of scientists with research
and commercial experience in high-level mathematical modeling, programming and
molecular genetics. Two products currently marketed by DNAPrint(TM),
DNAWitness(TM) and the ANCESTRYbyDNA(TM), are a direct result of focused
research by the DNAPrint(TM) research and development team.
In addition to the currently marketed products, DNAPrint(TM) is using
proprietary human genome research methods to develop pharma-predictive tests
for matching patients with drugs based on their genetic constitution, and to
discover disease genes for the development of new drugs. DNAPrint(TM) will
continue to develop new forensic genomics and consumer genomics testing
products. The Company is traded on the Nasdaq OTC Bulletin Board under the
ticker symbol DNAP. For more information about the company, please visit
www.dnaprint.com.
For more information on our genealogical DNA derived test,
ANCESTRYbyDNA(TM) 2.0, visit us on line at www.ancestrybydna.com, helping
everyone to understand their genetic heritage.
All statements in this press release that are not historical and are
forward-looking statements within the meaning of Section 21E of the Securities
Exchange Act, as amended, are subject to risks and uncertainties that could
cause actual results to differ materially from those projected, including, but
not limited to, uncertainties relating to technologies, product development,
manufacturing, market acceptance, cost and pricing of DNAPrint's(TM) products,
dependence on collaborations and partners, regulatory approvals, competition,
intellectual property of others, and patent protection and litigation.
DNAPrint(TM) genomics, Inc. expressly disclaims any obligation or undertaking
to release publicly any updates or revisions to any forward-looking statements
contained herein to reflect any change in DNAPrint's(TM) expectations with
regard thereto or any change in events, conditions, or circumstances on which
any such statements are based.
Media and Press Contacts
Richard Gabriel
DNAPrint(TM) genomics, Inc.
CEO/President
(941) 366-3400
About Athena Capital Partners, Inc.
Athena Capital Partners, Inc. (Member NASD-SIPC) offers capital markets
expertise for emerging companies seeking venture or growth capital. It also
organizes and assists alternative investment funds in fund raising. Athena
provides assistance through capital solutions, including debt and equity
capital raises, as well as with merger and acquisition investment banking
services. Headquartered in Tampa, Florida, the company specializes in helping
Florida-based companies, or companies trying to enter the flourishing Florida
market. Athena specifically targets companies in the life sciences and health
care sectors having leading edge and breakthrough technologies and funds in
areas with high market potential or unique strategies.
Media and Press Contacts
Kevin Cimino
Athena Capital Partners
813-242-8907
SOURCE DNAPrint genomics, Inc.
-0- 12/03/2003
/CONTACT: Richard Gabriel, CEO - President, DNAPrint(TM) genomics, Inc.,
+1-941-366-3400; or Kevin Cimino of Athena Capital Partners, +1-813-242-8907/
/Web site: http://www.dnaprint.com
http://www.ancestrybydna.com /
(DNAP)
CO: DNAPrint genomics, Inc.; Athena Capital Partners, Inc.; La Jolla Cove
Investors
ST: Florida
IN: FIN MTC OTC HEA
SU: FNC
*** end of story ***
11:35 PM, Channel 7 in Los Angeles
Wayne Joseph is a 51-year-old high school principal in Chino whose family emigrated from the segregated parishes of Louisiana to central Los Angeles in the 1950s, as did mine. Like me, he is of Creole stock and is therefore on the lighter end of the black color spectrum, a common enough circumstance in the South that predates the multicultural movement by centuries. And like most other black folk, Joseph grew up with an unequivocal sense of his heritage and of himself; he tends toward black advocacy and has published thoughtful opinion pieces on racial issues in magazines like Newsweek. When Joseph decided on a whim to take a new ethnic DNA test he saw described on a 60 Minutes segment last year, it was only to indulge a casual curiosity about the exact percentage of black blood; virtually all black Americans are mixed with something, he knew, but he figured it would be interesting to make himself a guinea pig for this new testing process, which is offered by a Florida-based company called DNA Print Genomics Inc. The experience would at least be fodder for another essay for Newsweek. He got his kit in the mail, swabbed his mouth per the instructions and sent off the DNA samples for analysis.
Now, I have always believed that what is now widely considered one of slavery's worst legacies ? the Southern "one-drop" rule that indicted anyone with black blood as a nigger and cleaved American society into black and white with a single stroke ? was also slavery's only upside. Of course I deplore the motive behind the law, which was rooted not only in white paranoia about miscegenation, but in a more practical need to maintain social order by keeping privilege and property in the hands of whites. But by forcing blacks of all complexions and blood percentages into the same boat, the law ironically laid a foundation of black unity that remains in place today. It's a foundation that allows us to talk abstractly about a "black community" as concretely as we talk about a black community in Harlem or Chicago or South-Central (a liberty that's often abused or lazily applied in modern discussions of race). And it gives the lightest-skinned among us the assurance of identity that everybody needs in order to feel grounded and psychologically whole ? even whites, whose public non-ethnicity is really ethnicity writ so large and influential it needs no name. Being black may still not be the most advantageous thing in the world, but being nothing or being neutral ? the rallying cry of modern-day multiculturalists ? has never made any emotional or real-world sense. Color marks you, but your membership in black society also gives you an indestructible house to live in and a bed to rest on. I can't imagine growing up any other way.
Wayne Joseph can't, either. But when the results of his DNA test came back, he found himself staggered by the idea that though he still qualified as a person of color, it was not the color he was raised to think he was, one with a distinct culture and definitive place in the American struggle for social equality that he'd taken for granted. Here was the unexpected and rather unwelcome truth: Joseph was 57 percent Indo-European, 39 percent Native American, 4 percent East Asian ? and zero percent African. After a lifetime of assuming blackness, he was now being told that he lacked even a single drop of black blood to qualify.
"My son was flabbergasted by the results," says Joseph. "He said, 'Dad, you mean for 50 years you've been passing for black?'" Joseph admits that, strictly speaking, he has. But he's not sure if he can or wants to do anything about that at this point. For all the lingering effects of institutional racism, he's been perfectly content being a black man; it has shaped his worldview and the course of his life in ways that cannot, and probably should not, be altered. Yet Joseph struggles to balance the intellectual dishonesty of saying he's black with the unimpeachable honesty of a lifelong experience of being black. "What do I do with this information?" he says, sounding more than a little exasperated. "It was like finding out you're adopted. I don't want to be disingenuous with myself. But I can't conceive of living any other way. It's a question of what's logical and what's visceral."
Race, of course, has always been a far more visceral matter than a logical one. We now know that there is no such thing as race, that humans are biologically one species; we know that an African is likely to have more in common genetically with a European thousands of miles away than with a neighboring African. Yet this knowledge has not deterred the racism many Europeans continue to harbor toward Africans, nor the wariness Africans harbor toward Europeans. Such feelings may never be deterred. And despite all the loud assertions to the contrary, race is still America's bane, and its fascination; Philip Roth's widely acclaimed last novel set in the 1990s, The Human Stain, features a Faustian protagonist whose great moral failing is that he's a black man who's been passing most of his life for white (the book has been made into a movie due in theaters next month).
Joseph recognizes this, and while he argues for a more rational and less emotional view of race for the sake of equity, he also recognizes that rationality is not the same thing as fact. As much as he might want to, he can't simply refute his black past and declare himself white or Native American. He can acknowledge the truth but can't quite apply it, which makes it pretty much useless to other, older members of his family. An aunt whom he told about the test results only said that she wasn't surprised. "When I told my mother about the test, she said to me, 'I'm too old and too tired to be anything else,'" recalls Joseph. "It makes no difference to her. It's an easy issue."
After recovering from the initial shock, Joseph began questioning his mother about their lineage. He discovered that, unbeknownst to him, his grandparents had made a conscious decision back in Louisiana to not be white, claiming they didn't want to side with a people who were known oppressors. Joseph says there was another, more practical consideration: Some men in the family routinely courted black women, and they didn't want the very public hassle such a pairing entailed in the South, which included everything from dirty looks to the ignominy of a couple having to separate on buses and streetcars and in restaurants per the Jim Crow laws. I know that the laws also pointedly separated mothers from sons, uncles from nephews, simply because one happened to be lighter than the other or have straighter hair. Determinations of race were entirely subjective and imposed from without, and the one-drop rule was enforced to such divisive and schizophrenic effects that Joseph's family ? and mine ? fled Louisiana for the presumably less boundary-obsessed West. But we didn't flee ourselves, and didn't expect to; we simply set up a new home in Los Angeles. The South was wrong about its policies but it was right about our color. It had to be.
Joseph remains tortured by the possibility that maybe nobody is right. The essay he thought the DNA test experience would prompt became a book that he's already 150 pages into. He doesn't seem to know how it'll end. He's in a kind of limbo that he doesn't want and that I frankly wouldn't wish on anyone; when I wonder aloud about taking the $600 DNA test myself, Joseph flatly advises against it. "You don't want to know," he says. "It's like a genie coming out of a bottle. You can't put it back in." He has more empathy for the colorblind crowd than he had before, but isn't inclined to believe that the Ward Connerlys and other professed racial conservatives of the world have the best interests of colored people at heart. "I see their point, but race does matter, especially with things like medical research and other social trends," he says of Connerly's Proposition 54, the much-derided state measure that seeks to outlaw the collection of ethnic data that will be voted on in the recall election next Tuesday. "Problems like that can't just go away." For the moment, Joseph is compelled to try to judge individually what he knows has always been judged broadly, to reconcile two famously opposed viewpoints of race not for the sake of political argument ? he has made those ? but for his own peace of mind. He's wrestling with a riddle that will likely outlive him, though he doesn't worry that it will be passed on to the next generation ? his ex-wife is black, enough to give his children the firm ethnic identity he had and that he embraced for most of his life. "The question ultimately is, are you who you say you are, or are you who you are genetically?" he muses. The logical ? and visceral ? answer is that it's not black and white.
« Home « Top Stories
Print
Get a print-friendly version of this story.
Also in Top Stories
Miami Vice
By Tom Hayden
Nov 20, 2003
A No-Solution Energy Bill
By Bracken Hendricks
By Skye Perryman
Nov 20, 2003
The Identity Game
By Alicia Young
Nov 20, 2003
A Real Senior Moment
By Bertie Evans
By Robert Porter
By Gene Smith
By Dick Wisott
Nov 20, 2003
Neocons Leak Bad Intelligence
By Jim Lobe
Nov 20, 2003
Read other stories by Erin Aubry Kaplan
Email
Send this story to a friend.
From:
To:
Optional Message:
Support AlterNet
Do you value the information you're getting from AlterNet? Please show your support with a tax-deductible donation.
Mobile/PDA Writer Guidelines Privacy Policy Partners Acknowledgments Contact Us
© 2003 Independent Media Institute. All rights reserved. Reproduction by Syndication Service only.
More News (PR NEWSWIRE) Nightline: Friday Night November 21, 2003 Will Air a Segment on D
A Testing And Its Dramatic Impact on Our Heritage
Nightline: Friday Night November 21, 2003 Will Air a Segment on DNA Testing And
ts Dramatic Impact on Our Heritage
SARASOTA, Fla., Nov. 21 /PRNewswire-FirstCall/ -- Nightline, airing on ABC
Friday night November 21, 2003, will discuss and review DNA testing and our
perception of our heritage and what we often call 'Race.' This dramatic
disclosure will feature interviews from Dr. Mark Shriver, Assistant Professor
of Anthropology and Genetics at Penn State University, Dr. Tony Frudakis,
Chief Scientific Officer at DNAPrint(TM) genomics, Inc.
(OTC Bulletin Board: DNAP), and Mr. Wayne Joseph. The show will explore DNA
testing and its potential impact on all of us. Watch Nightline, guaranteed to
make you think! Check a local ABC affiliate for times in other time zones, but
the show typically airs at 11:30 PM Eastern time, usually right after the
local news.
About DNAPrint(TM) genomics, Inc.
DNAPrint(TM) genomics Inc. was founded by a team of scientists with
research and commercial experience in high-level mathematical modeling,
programming and molecular genetics. The DNAWitness(TM) and the
ANCESTRYbyDNA(TM) analysis is a direct result of focused research by the DNAP
research and development team.
In addition, using proprietary human genome research methods, the Company
develops pharma-predictive tests for matching patients with drugs based on
their genetic constitution, discovers disease genes for the development of new
drugs and develops new forensic genomics and consumer genomics-testing
products. The Company is traded on the NASDAQ OTC Bulletin Board under the
ticker symbol: DNAP. For more information about the company, please visit
www.dnaprint.com .
For more information on our genealogical DNA derived test,
ANCESTRYbyDNA(TM) 2.0, visit us on-line at www.ancestrybydna.com , helping
everyone to understand their genetic heritage.
All statements in this press release that are not historical are
forward-looking statements within the meaning of Section 21E of the Securities
Exchange Act, as amended. Such statements are subject to risks and
uncertainties that could cause actual results to differ materially from those
projected, including, but not limited to, uncertainties relating to
technologies, product development, manufacturing, market acceptance, cost and
pricing of DNAPrint's(TM) products, dependence on collaborations and partners,
regulatory approvals, competition, intellectual property of others, and patent
protection and litigation. DNAPrint(TM) genomics, Inc. expressly disclaims any
obligation or undertaking to release publicly any updates or revisions to any
forward-looking statements contained herein to reflect any change in
DNAPrint's(TM) expectations with regard thereto or any change in events,
conditions, or circumstances on which any such statements are based.
Media and Press Contacts
Richard Gabriel
DNAPrintTM genomics, Inc.
CEO/President
(941) 366-3400
SOURCE DNAPrint(TM) genomics, Inc.
-0- 11/21/2003
/CONTACT: Richard Gabriel, CEO and President of DNAPrint(TM) genomics,
+1-941-366-3400/
/Web site: http://www.dnaprint.com /
(DNAP)
CO: DNAPrint(TM) genomics, Inc.; ABC
ST: Florida
IN: MTC OTC TVN HEA ENT
SU:
*** end of story ***
Ok , Then why are a lot of the "so called quote sites" showing .062 as the close. Your quote site says .069, mine says .069, I use Mytrack, but a lot of other people who dont have the tools we do say .062.
A "T' trade by itself is an after hours adjustment trade ,I agree, but when it is continually used to show the closing price as way lower, it is manipulation and is called "painting the tape".
The late trades of 100.000 etc are called "painting the tape" It is a late trade denoted by the letter "T". Here is an explanation.
"Painting the tape" is a term used in connection with a market manipulation of a security. It means that fictitious trades have been reported on the consolidated tape of an exchange but are not submitted for trade matching and clearing purposes. Fraudsters engage in this type of "trading" to increase the apparent trading volume of a security, change the reported closing price, or misrepresent the market of that security.
http://sec.broaddaylight.com/sec/FAQ_20_748.shtm